Climb Bio Inc Dossier
Qualitative Analysis
Business overview
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) is a clinical-stage biotechnology company focused on developing targeted monoclonal antibodies for patients with immune-mediated and autoimmune diseases. The company's pipeline is anchored by two lead candidates: budoprutug (formerly known as TNT119), an anti-CD19 monoclonal antibody designed for deep B-cell depletion to treat B-cell mediated diseases such as primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE); and CLYM116 (formerly MIL116), an anti-APRIL monoclonal antibody in-licensed from Mabworks in January 2025, which is being developed for the treatment of IgA nephropathy (IgAN). Climb Bio operates as a pre-revenue development-stage entity, with its future commercial success dependent on clinical trial outcomes and regulatory approvals.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of lead asset budoprutug (an anti-CD19 monoclonal antibody) across three key indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE).
Expected impact: Establish clinical proof-of-concept and differentiate budoprutug as a best-in-class B-cell depleting therapy.
Developing CLYM116, an Fc-engineered anti-APRIL monoclonal antibody utilizing a novel 'sweeper' mechanism to promote lysosomal degradation of APRIL, targeting IgA nephropathy (IgAN).
Expected impact: Provide a best-in-class therapeutic option with rapid, deep, and durable IgA depletion and less frequent dosing.
Optimizing the productivity and scalability of the manufacturing process for budoprutug by implementing a cell line switch to support later-stage clinical development.
Expected impact: Enhance scalability, reduce long-term manufacturing costs, and secure robust supply for late-stage clinical and commercial use.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquire the rights to budoprutug (formerly TNT119), an anti-CD19 monoclonal antibody, enabling a strategic pivot toward autoimmune and immune-mediated inflammatory diseases.
Financial impact: Resulted in a non-recurring acquired IPR&D charge of $51.7 million in 2024 and shifted the company's primary R&D allocation to budoprutug clinical trials.
Strategic Partnerships
Secured exclusive rights to develop and commercialize CLYM116 (formerly MIL116) outside of Greater China, expanding Climb Bio's pipeline into the APRIL-targeted space for IgA nephropathy.
Terms: Climb Bio paid an upfront cash payment of $9.0 million in January 2025 and is eligible to pay additional development, regulatory, and commercial milestones, plus royalties on net sales outside Greater China.